e-therapeutics (LSE: ETX)

Last close As at 19/04/2024


−0.25 (−2.45%)

Market capitalisation


e-therapeutics is a UK biotech using its proprietary computational biology and RNAi platforms to discover novel disease targets and therapies. The company is specifically focused on leveraging its expertise to design treatments targeting one cell type in the liver, hepatocytes.

The application of AI platforms in the pharmaceutical industry has evolved significantly and has matured to a stage where the first purely AI-generated candidates have entered clinical trials. We believe that platforms capable of designing novel, effective drugs and with the ability to identify new disease targets will offer an advantage over competitors.

Latest Insights

Healthcare | edison tv

e-therapeutics showcase

Healthcare | Update

e-therapeutics — More to come in RNAi therapy discovery

Healthcare | Initiation

e-therapeutics — Enhancing siRNA drug discovery with LLMs




Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Arron Aatkar

Associate analyst

Key Management

  • Ali Mortazavi


  • Laura Roca-Alonso

    Chief business officer

Balance Sheet

Forecast net debt (£m)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual (22.7) (40.2) (25.6)
Relative (24.0) (43.2) (25.5)
52 week high/low 23.1p/8.1p


e-therapeutics is leveraging its computational biology platform, HepNet, to discover novel hepatocyte-associated targets and develop novel siRNA medicines using its RNAi platform, GalOmic. Within HepNet, it utilises advanced AI systems, such as LLMs, to extract non-obvious insights across disparate data domains to streamline its drug discovery workflow. There continues to be a diverse range of hepatocyte-associated disease indications (not restricted to diseases of the liver) with untapped targets, providing scope for new treatments to have a unique offering. The company introduced preclinical assets ETX-291 and ETX-148 in late-2023, which silence genes implicated in cardiometabolic disease and haemophilia, respectively. In January 2024, the company introduced several more preclinical assets, including ETX-407 for dAMD, and ETX-312 for MASH; IND/CTA-enabling studies for these assets are to commence in due course.

Y/E Jan Revenue (£m) EBITDA (£m) PBT (£m) EPS (fd) (p) P/E (x) P/CF (x)
2022A 0.5 (9.4) (9.5) (1.65) N/A N/A
2023A 0.5 (9.8) (9.8) (1.54) N/A N/A
2024E N/A N/A N/A N/A N/A N/A
2025E N/A N/A N/A N/A N/A N/A


edison tv


e-therapeutics showcase



e-therapeutics — Enhancing siRNA drug discovery with LLMs


Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free